Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
Recruiting · NCT05366829 · Registry updated 2026-01-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-01-20 | NCT05366829 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioGene Pharmaceutical Ltd. | 1 |
| Natera, Inc. | 45 |
| Rutgers, The State University of New Jersey | 154 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Montefiore Medical Center | The Bronx | United States | 1 |
| Rutgers Cancer Institute of New Jersey | New Brunswick | United States | 223 |